Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-γ-modulating activity, on nitric oxide bioavailability and atherosclerotic change
- 1 May 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 26 (5), 964-972
- https://doi.org/10.1097/hjh.0b013e3282f52c36
Abstract
Objective Telmisartan is a unique angiotensin II (Ang II) receptor blocker (ARB) with selective peroxisome proliferator-activated receptor-γ (PPARγ). We therefore investigated the effects of telmisartan on endothelial function and atherosclerotic change in genetically hyperlipidemic rabbits, compared with candesartan, an ARB without PPARγ activity. Methods A total of 30 Watanabe heritable hyperlipidemic (WHHL) rabbits equally derived (n = 6 each) were treated with (1) vehicle (control), (2) GW9662, a PPARγ antagonist (0.5 mg/kg per day), (3) telmisartan (5 mg/kg per day), (4) telmisartan + GW9662, (5) candesartan (5 mg/kg per day) for 8 weeks. After treatment, acetylcholine (ACh)-induced nitric oxide production was measured as a surrogate for endothelium protective function, and vascular nitrotyrosine (a product of superoxide and nitric oxide) was measured for assessing dysfunctional endothelial nitric oxide synthase activity. Plaque area was quantified by histology. Results Telmisartan increased ACh-induced nitric oxide by 5.5 nmol/l, significantly more than control. Interestingly, cotreatment with GW9662 significantly attenuated telmisartan-induced ACh-induced nitric oxide almost to the levels observed with candesartan. Vascular nitrotyrosine concentration was 1.4 pmol/mg protein in the control group and significantly higher than that in the telmisartan or candesartan group. The lowest nitrotyrosine concentration was observed in the telmisartan group, which was significantly lower than that in the candesartan or telmisartan + GW9662 group. Histology of the thoracic aorta revealed that the plaque area was more significantly decreased in the telmisartan group than in the candesartan or telmisartan + GW9662 group. Conclusion In addition to a class effect of ARBs, telmisartan may have additional effects on nitric oxide bioavailability and atherosclerotic change through its PPARγ-mediated effects in genetically hyperlipidemic rabbits.Keywords
This publication has 26 references indexed in Scilit:
- Effects of Angiotensin II on NO Bioavailability Evaluated Using a Catheter-Type NO SensorHypertension, 2006
- Evaluation of bioavailability of nitric oxide in coronary circulation by direct measurement of plasma nitric oxide concentrationProceedings of the National Academy of Sciences of the United States of America, 2005
- Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ ActivityCirculation, 2004
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Measurement of acetylcholine-induced endothelium-derived nitric oxide in aorta using a newly developed catheter-type nitric oxide sensorBiochemical and Biophysical Research Communications, 2003
- Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective ModulatorMolecular Endocrinology, 2003
- The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trialMetabolism, 2003
- Peroxisome proliferator‐activated receptors in the cardiovascular systemBritish Journal of Pharmacology, 2000
- Expression of Cellular FLICE-Inhibitory Protein in Human Coronary Arteries and in a Rat Vascular Injury ModelThe American Journal of Pathology, 2000
- Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutaseArchives of Biochemistry and Biophysics, 1992